Quick Answer
Biohaven Ltd. reported Net Income of -$738.82 million for fiscal year 2025.
Biohaven Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$738.82M +12.7% |
-$846.42M -107.4% |
-$408.17M +28.4% |
-$570.28M -166.7% |
-$213.80M -80.2% |
-$118.67M |
| Diluted EPS | -$6.86 +26.1% |
-$9.28 -62.0% |
-$5.73 +55.1% |
-$12.75 -134.8% |
-$5.43 -80.4% |
-$3.01 |
| Total Assets | $451.45M -26.6% |
$615.11M +19.9% |
$513.21M -22.5% |
$661.78M +365.8% |
$142.06M | — |
| Cash and Equivalents | $229.96M +132.0% |
$99.13M -60.1% |
$248.40M +21.2% |
$204.88M +169.4% |
$76.06M -7.8% |
$82.51M |
| Stockholders Equity | $52.07M -87.7% |
$423.44M -1.1% |
$427.98M -20.6% |
$538.77M +1453.1% |
$34.69M +106.7% |
$16.78M +16.1% |
| R&D Expense | $635.07M -20.2% |
$795.87M +113.2% |
$373.28M -14.6% |
$437.07M +140.8% |
$181.49M +84.3% |
$98.46M |
| Operating Income | -$745.38M +15.8% |
-$885.11M -103.0% |
-$436.05M +23.2% |
-$567.93M -159.4% |
-$218.90M -91.2% |
-$114.51M |
| Shares Outstanding | 132.78M +31.2% |
101.22M +24.8% |
81.12M +19.0% |
68.19M | 0 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$173.44M | -8.2% | +12.5% |
| Diluted EPS | September 30, 2025 | -$1.64 | +3.5% | +15.5% |
| Total Assets | September 30, 2025 | $409.12M | -19.9% | -25.7% |
| Cash and Equivalents | September 30, 2025 | $184.85M | +119.0% | +11.5% |
| Stockholders Equity | September 30, 2025 | -$17.16M | -105.4% | -112.8% |
| R&D Expense | September 30, 2025 | $141.17M | -10.4% | -23.4% |
| Operating Income | September 30, 2025 | -$169.38M | +4.9% | +20.0% |
| Shares Outstanding | September 30, 2025 | 105.80M | +11.5% | +0.0% |
- Biohaven Ltd. reported Net Income of -$738.82 million for fiscal year 2025.
- Biohaven Ltd. showed an increase of +12.7% in Net Income compared to the prior fiscal year.
- Biohaven Ltd. reported Diluted EPS of $6.86 per share (loss) for fiscal year 2025.
- Biohaven Ltd. showed an increase of +26.1% in Diluted EPS compared to the prior fiscal year.
- Biohaven Ltd. reported Total Assets of $451.45 million for fiscal year 2025.
- Biohaven Ltd. showed a decrease of -26.6% in Total Assets compared to the prior fiscal year.
- Biohaven Ltd. reported Cash and Equivalents of $229.96 million for fiscal year 2025.
- Biohaven Ltd. showed an increase of +132.0% in Cash and Equivalents compared to the prior fiscal year.
- Biohaven Ltd. reported Stockholders Equity of $52.07 million for fiscal year 2025.
- Biohaven Ltd. showed a decrease of -87.7% in Stockholders Equity compared to the prior fiscal year.
- Biohaven Ltd. reported R&D Expense of $635.07 million for fiscal year 2025.
- Biohaven Ltd. showed a decrease of -20.2% in R&D Expense compared to the prior fiscal year.
- Biohaven Ltd. reported Operating Income of -$745.38 million for fiscal year 2025.
- Biohaven Ltd. showed an increase of +15.8% in Operating Income compared to the prior fiscal year.
- Biohaven Ltd. reported Shares Outstanding of 132.78 million shares for fiscal year 2025.
- Biohaven Ltd. showed an increase of +31.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: